FTO inhibition drives MYC inhibition. The original CoH paper shows that Zan inhibits FTO which in turn influences MYC expression.
Prior preclinical models have shown Zantrene is functioning as a cardioprotective agent independently of FTO.
Unsure if that's the pathway, but I'd say not. A good way I like to think about it is if you turn a tree upside down - the trunk is cellular function as a whole, a main branch is FTO, and an offshoot from that main branch is MYC. You can't impact MYC without inhibiting FTO.
FTO inhibition drives MYC inhibition. The original CoH paper...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $288.0M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.69 | $1.57 | $387.6K | 237.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 807 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 2376 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |